At Cognesy, we are taking a neuroplasticity-first approach to develop compounds to treat neuropsychiatric disorders. Iโm thrilled to be a part of this team! #neuroplasticity#psychiatry#cognesy#pharmaceuticals
Today, we announce our Series D fundraising, successfully raising an additional $157m to progress our mission of healing mental health disorders.
Read more: https://t.co/EmIj9zDPIj
Today, all of us are extremely proud to share with you the closing of our Series C financing round. We believe that this reflects the growing recognition for more effective treatments in mental health.
Plenty more to come in the future. ๐
#mentalhealth
https://t.co/T2iPIcjp7F
So proud to welcome another member of the ATAI family: Viridia, developing N, N-Dimethyltryptamine (#DMT)!
We sat down w/ @amirahalidrus of @FierceBiotech to share more about the potential of rapid-acting #psychedelics for #mentalhealth
https://t.co/5xXr4WyfRD
Great to chat w/ @amirahalidrus of @FierceBiotech about our work with Neuronasal to develop a novel treatment for #concussions and #mTBI... This NAC-based nasal spray stands to avert potentially serious #mentalhealth complications for hundreds of thousands
https://t.co/vuFpwu4w1m
Great to chat w/ @amirahalidrus of @FierceBiotech about our work with Neuronasal to develop a novel treatment for #concussions and #mTBI... This NAC-based nasal spray stands to avert potentially serious #mentalhealth complications for hundreds of thousands
https://t.co/vuFpwu4w1m